We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Psychedelics – News and Features

News

Imaging Biomarker Predicts Response to Rapid Antidepressant

Signals dysfunction in brain system targeted by scopolamine - NIH study.
News

Identifying Protein 'Pockets' that Block Hallucinogens

Psychoactive drugs work by binding proteins in our brains and bodies and although these proteins have been a mystery, new research from the University of North Carolina is illuminating their structures.
News

Xceleron Announces New Investment and Move to Purpose-Built Laboratories in U.S.

Demand in translational science drives need for additional equipment.
News

Drug Boosts Growth Factor to Jump-Start Rapid Antidepressant Response

A study in mice has pinpointed a pivotal new player in triggering the rapid antidepressant response produced by ketamine. By deactivating a little-known enzyme, the drug takes the brakes off rapid synthesis of a key growth factor thought to lift depression.
News

Illicit Drug Use in the Pain Patient Population Decreases with Continued Drug Testing

Researchers from the Millenium Research Institute and the University of Cincinnati have utilised Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for the testing of illicit drugs.
News

CMO Laboratory Expands GMP Manufacturing Capabilities

Pharmatek Laboratories, Inc. have announced that it has added roller compaction to its solid oral dosage form manufacturing capabilities. The company has purchased two roller compactors, a pilot-scale. Both machines have been integrated into Pharmatek’s GMP facility and are ready for GMP manufacturing.
News

Quotient Bioresearch to Highlight Integrated Early Stage Drug Development Platforms at FIP Pharmaceutical Sciences World Congress 2010

The Translational Pharmaceutics platform has redefined early development processes by integrating the development and provision of drug products with clinical testing.
News

New Hope for Javelin's Pain Candidate but Safety Concerns Remain

An external review of Phase III data for Javelin Pharmaceuticals' Ereska has found previously negative top-line results for its primary endpoint to be statistically significant. While the findings offer renewed hope for the company, ketamine's association with drug abuse and its well-documented hallucinatory effects represent key weaknesses in the market place, despite Ereska's proven efficacy.
News

Evotec Starts Phase I with EVT 103, an NR2B-selective NMDA Receptor Antagonist

EVT 103 is currently planned to enter clinical development for treatment-resistant depression in collaboration with Roche.
News

Randox in the Racing World - Sensitive Screening Solutions

Randox are working with the international racing laboratories to maintain the integrity of racing, to make certain animals are winning races on their own natural merits and to ensure the safety of the animals and jockeys is maintained.
Advertisement